SCHEDULE: BlackRock Discloses 6.7% Stake in Immuneering Corp

BlackRock, Inc. has reported beneficial ownership of 6.7% of Immuneering Corp's Class A Stock as of June 30, 2026.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating it beneficially owns 4,356,235 shares of Immuneering Corp's Class A Stock.
• This ownership stake represents 6.7% of the class of securities.
• The filing date for this event is June 30, 2026.
• BlackRock, Inc. is classified as a holding company (HC) for reporting purposes.
• The filing specifies that BlackRock, Inc. has sole voting power over 4,314,766 shares and sole dispositive power over 4,356,235 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development. While BlackRock's investment is a positive signal, the filing itself is a standard disclosure without new strategic information or performance metrics.

Positives

• BlackRock, a significant institutional investor, has taken a notable stake in Immuneering Corp, potentially signaling confidence in the company's prospects.
• The clear disclosure of ownership percentages and voting/dispositive power provides transparency to the market.

Risks

• While BlackRock's investment is in the ordinary course of business, any significant shift in their holdings could impact Immuneering Corp's stock price.
• The filing does not detail the specific investment strategy or rationale behind BlackRock's stake, leaving potential future intentions open to interpretation.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from BlackRock regarding its future intentions with Immuneering Corp. The certification indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that the filing of a Schedule 13G by BlackRock, Inc. signifies a substantial institutional investment in Immuneering Corp. This type of filing is common when an institutional investor crosses a certain ownership threshold and is typically seen as a positive signal, indicating confidence from a major market player.

Stakeholder Impact

• Shareholders: The investment by a major institution like BlackRock may be perceived positively, potentially increasing investor confidence and influencing share price.
• Management: The increased institutional ownership may lead to greater scrutiny and engagement from BlackRock regarding corporate strategy and governance.
• Market Analysts: This filing provides data for analysts to incorporate into their valuation models and investment recommendations for Immuneering Corp.

Next Steps

• Monitor future filings from BlackRock, Inc. for any changes in their beneficial ownership of Immuneering Corp.
• Observe Immuneering Corp's performance and strategic developments to understand the context of BlackRock's investment.

Key Dates

Recommendation

The filing indicates a significant institutional investment by BlackRock, which is generally a positive signal. However, it is a passive ownership disclosure (Schedule 13G) and does not provide new operational or financial performance data for Immuneering Corp. Therefore, a 'hold' recommendation is appropriate, pending further information on the company's performance and BlackRock's specific investment thesis.

Keywords

Immuneering Corp, BlackRock, Schedule 13G, Class A Stock, Institutional Investor, Beneficial Ownership, Securities Exchange Act